Earlier, we had reported the potential of VNPP433-3β in treating preclinical models of castration-resistant prostate cancer by promoting degradation of f-AR and preventing phosphorylation of eIF4E by depleting Mnk1/2 [11,30]. This evidence concerns the gene MKNK1 and prostate cancer.